Table 4.
Changes in the clinical manifestations assessed by the Pelvic Venous Clinical Severity Score (PVCSS) in the micronized purified flavonoid fraction (MPFF, n = 42) and control (n = 41) groups
| Parameter | PVCSS score (mean ± SD) | Change D61–D0 (mean ± SD) | P value (intra-group) | P value (inter-group) | |
|---|---|---|---|---|---|
| Day 0 | Day 61 | ||||
| MPFF group | |||||
| Pain | 1.4 ± 0.9 | 0.9 ± 0.6 | 0.5 ± 0.7 | < 0.001 | 0.003 |
| Heaviness | 1.2 ± 0.9 | 0.8 ± 0.8 | 0.4 ± 0.7 | 0.001 | 0.003 |
| Discomfort | 1.3 ± 1.0 | 0.7 ± 0.6 | 0.6 ± 0. 7 | < 0.001 | < 0.001 |
| Pain in the sacrum and coccyx | 1.4 ± 1.0 | 1.0 ± 0.9 | 0.4 ± 0.6 | < 0.001 | 0.012 |
| Urination disorder | 1.2 ± 1.0 | 0.8 ± 0.9 | 0.4 ± 0.8 | 0.005 | 0.033 |
| Atypical varicosis | 0.8 ± 1.1 | 0.6 ± 0.9 | 0.2 ± 0.7 | NS | NS |
| Dyspareunia | 1.0 ± 0.9 | 0.8 ± 0.8 | 0.2 ± 0.5 | 0.008 | NS |
| Menstrual disorders | 0.8 ± 0.9 | 0.7 ± 0.9 | 0.1 ± 0.5 | NS | NS |
| Tenderness | 0.8 ± 1.0 | 0.4 ± 0.7 | 0.3 ± 0.5 | 0.001 | 0.024 |
| Edema | 0.7 ± 1.0 | 0.4 ± 0.7 | 0.2 ± 0.6 | 0.018 | NS |
| Summary score | 10.5 ± 6.0 | 7.1 ± 4.6 | 3.4 ± 3.4 | < 0.001 | < 0.001 |
| Control group | |||||
| Pain | 1.4 ± 0.7 | 1.4 ± 0.8 | – 0.0 ± 0.4 | NS | – |
| Heaviness | 1.3 ± 0.8 | 1.4 ± 0.9 | – 0.1 ± 0.4 | NS | – |
| Discomfort | 1.1 ± 0.8 | 1.2 ± 0.8 | – 0.2 ± 0.5 | NS | – |
| Pain in the sacrum and coccyx | 1.3 ± 1.0 | 1.3 ± 1.0 | 0.0 ± 0.4 | NS | – |
| Urination disorder | 0.8 ± 1.0 | 0.9 ± 1.1 | – 0.1 ± 0.3 | NS | – |
| Atypical varicosis | 0.7 ± 1.0 | 0.7 ± 0.9 | 0.0 ± 0.2 | NS | – |
| Dyspareunia | 1.3 ± 1.0 | 1.3 ± 0.9 | – 0.0 ± 0.4 | NS | – |
| Menstrual disorders | 1.1 ± 1.0 | 1.1 ± 1.0 | 0.0 ± 0.4 | NS | – |
| Tenderness | 1.0 ± 1.0 | 1.0 ± 1.0 | 0.0 ± 0.4 | NS | – |
| Edema | 0.9 ± 1.1 | 0.8 ± 1.0 | 0.0 ± 0.4 | NS | – |
| Summary score | 11.0 ± 5.4 | 11.2 ± 5.6 | – 0.2 ± 1.6 | NS | – |
SD standard deviation